Compass – Bispecific Misses OS Endpoint

Summary Compass Therapeutics reported that its DLL4xVEGF-A bispecific antibody, tovecimig, failed to meet the overall survival (OS) endpoint in a Phase 2/3 trial in biliary tract cancer, despite showing a statistically significant progression-free survival (PFS) benefit. What Happened In the Phase 2/3 study, patients receiving…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Weekly Market Insight

Lilly – Ajax JAK2 Deal ($2.3B)
argenx Acquires Forte for $2.2 Billion
Ultrasound Genetic Medicine Platform Advances Toward Clinic
AstraZeneca Licenses Dizal’s Zegfrovy for Up to $1.5B